Supplementary Table: Gleason Score 3+4 vs. 4+3: Correlation of Biopsy and Radical Prostatectomy Grade
| Biopsy Grade | RP Grade | No. of Cases | Author | Years of Study |
|---|---|---|---|---|
| 3+4=7 4+3=7 |
26.7% upgraded 53.3% downgraded |
217 60 |
Burdick13 | 1996-2005 |
| 3+4=7 4+3=7 |
35% upgraded 49% downgraded |
148 57 |
Grober14 | 1997-2001 |
| 3+4=7 4+3=7 |
29% upgraded 51% downgraded |
201 78 |
Kang15 | 1988-2005 |
| 3+4=7 4+3=7 |
33% upgraded 33% downgraded |
52 27 |
Fanning16 | 2003-2008 |
| 3+4=7 4+3=7 |
28% upgraded 33% downgraded |
112 3 |
D'Amico21 | 1988-1997 |
| 3+4=7 4+3=7 |
44% upgraded 48% downgraded |
25 25 |
King20 | 2000-2003 |
| 3+4=7 | 25% upgraded | 216 | Freedland17 | 1996-2005 |
| 3+4=7 4+3=7 |
27% upgraded 36% downgraded |
734 226 |
Moussa18 | 2000-2007 |
| 3+4=7 | 55% upgraded | 181 | Tilki19 | 2004-2007 |
| 3+4=7 4+3=7 |
26% upgraded 40% downgraded |
1267 524 |
Current | 2004-2010 |
Relation of Radical Prostatectomy Tumor Volume to Post-Operative Progression
| Institution(yr) | No. Cases | Yrs of Study | Mean f.u. mos. | Totally embedded | T. vol parameter | Mean t.vol. cc.(median) | Independent predictor |
|---|---|---|---|---|---|---|---|
| U.Miami(2003) | 692 | 1992-2002 | 52 | Yes | Percent (estimate) | Yes | |
| U.Innsbruck(2006) | 102 | 1988-2005 | Yes | Volume (planimetry) | 1.27 | Yes | |
| Vanderbilt(2006) | 431 | 2000-2002 | 25.4 | Yes | Volume (planimetry) | 3.28 | Yes |
| Vivantes Hospitals(2007) | 528 | 1996+2003 | 48.8 (46.4) | Yes | Volume (planimetry) | 4 | Yes |
| U.Heidelberg(2007) | 506 | 1999-2006 | 37.3 | Volume (?Technique) | 3.58(no prog) 3.3(prog) | Yes | |
| U.Hamburg(2007) | 780 | 1996-2003 | 46.7 (43.4) | No | Volume (planimetry) | 6.6 | Yes |
| Keio U.(2009) | 164 | Yes | Volume MTD | 3.9 | Yes | ||
| Stanford(2009) | 739 | 1984-2004 | (91.7) | Yes | Volume (planimetry) | (2.4) | Yes |
| U. of Tokyo(2010) | 364 | 2000-2009 | (37.4) | Yes | MTD | Yes | |
| Duke U.(2010) | 3057 | 1988-2008 | Yes | Percent Volume (estimated) | No | ||
| Indiana U.(2005) | 364 | (12) | No | MTD | 2.5 | Yes | |
| Indiana U.(2005) | 459 | 44.3 | No | Percent (Visual Estimate) | 24%(no prog) 36%(prog) | No | |
| Henri Mondor Hospital(2003) | 200 | 1992-1998 | 64 | Yes | Volume (planimetry) | 1.35 | No |
| Baylor(2004) | 1302 | 1983-2000 | (46) | Yes | Volume (planimetry) | (2.16 Pre '95) (1.25 Post '95) | No |
| Brigham & Women's(2005) | 781 | 1986-2002 | 65 | No | MTD | No | |
| Nijmegen(2008) | 542 | 1992-2005 | (39.5) | Yes | Volume (planimetry) MTD | (2.0) | No |
| UCSF(2009) | 856 | 1998-2007 | 24(no prog) | Yes | Volume (estimate) | (1.5) | No |
| U.Western Australia(2010) | 2385 | 1998-2007 | 32.3 (no prog) | Yes | Volume (planimetry) | 3.4 | No |
| U.Campinas(2010) | 305 | 1997-2008 | 30.2 | Yes | Volume (point count) | No | |
| Erasmus(2010) | 305 | 1993-2000 | 96 (98) | Yes | Volume (planimetry) | 1.05 (0.6) |
No |
Multivariate Analyses Predicting Progression Following Radical Prostatectomy
| Institution | Tumor Volume, Gleason Score, PSA |
EPE, Margins, Age |
SVI, LN |
|---|---|---|---|
| U.Miami | Tumor volume p=0.017-0.001 Gleason score p=NS - 0.018** PSA (>10) p=0.005 |
EPE p<0.0001 Margins p=NS Age p=0.02-.005 |
SVI p=0.021 LN p=NS |
| Innsbruck | Tumor volume p<0.001 Gleason score p<0.05 |
pStage p<0.001 Margins p<0.045 |
SVI p<0.05 |
| Vanderbilt | Tumor volume p=0.04 Gleason score p=0.005 PSA p=NS |
pStage p=NS Margins p=0.008 |
LN p=0.04 |
| Vivantes | Tumor volume p=NS Gleason score p<0.001 |
pStage p=NS Margins p=NS |
LN p=0.008 |
| Hamburg | Tumor volume p=0.002 Gleason score p<0.001= PSA p=0.023 |
EPE p<0.001 Margins p=NS |
SVI p=NS LN p=0.042 |
| Keio | Tumor volume p=0.015 Gleason score p=0.013 |
pStage p=NS Margins p=0.005 |
|
| Stanford | Tumor volume p=0.01 Gleason score p<0.001 PSA p=NS |
EPE p<0.001 Margins p<0.001 |
SVI p=NS LN p<0.001 |
| Duke | Tumor volume p=0.031 Gleason score p<0.001 PSA p<0.001 |
pStage=0.05 Margins p<0.001 |
SVI p<0.001 |
| Indiana | Tumor volume p=0.011 Gleason score p<0.0001 |
pStage p=NS Margins p=NS |
SVI p=NS |
| Tokyo | Tumor volume p=0.037 Gleason score p=0.019 |
pStage p=0.003 Margins p<0.001 |
|
| Mondor | Tumor volume p=NS Gleason score p=0.04 |
pStage p=0.0002 Margins p=NS |
|
| Baylor | Tumor volume p=NS Gleason score p<0.001 |
EPE p<0.001 Margins p=NS |
SVI p<0.001 LN p<0.001 |
| Brigham & Women's | Tumor volume p=NS Gleason score p<0.0001 PSA p<0.0001 |
EPE p=NS Margins p=0.0004 |
SVI p<0.0001 |
| Nigmegen | Tumor volume p=NS Gleason score p<0.05* |
pStage p<0.05* Margins p<0.05 |
|
| UCSF | Tumor volume p=NS Gleason score p=0.001 PSA (>10) p=0.02-0.001 |
EPE p=0.004 Margins p=0.042 |
SVI p=0.034 LN p=NS |
| U.Western Australia | Tumor volume p=NS Gleason score p<0.001 PSA p=0.001 |
EPE p<0.001 Margins p<0.001 |
SVI p<0.001 |
| Campinas | Tumor volume p=NS Gleason score p=0.01 |
pStage p=0.03 Margins p<0.01 |
|
| Erasmus | Tumor volume p=NS Gleason score p<0.0001 |
pStage p=NS Margins p<0.0001 Age p=0.008 |
SVI p=NS |
** Range of p values for various outcomes relative to reference value
* Only p values greater or less than 0.05 were reported
© Copyright 2002-2010 Johns Hopkins University All Rights Reserved
